Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HRS-4729 injection in adults with overweight or obesity
CTR20262566Phase 2Active
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Jul 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-4729 in obesity, Overweight, sponsored by Fujian Shengdi Pharmaceuticals. Started Jul 2026; status: active.
02
Drugs
HRS-4729
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on CTR20262566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262566.